Glial cell line–derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

(2019) Alan L. Whone et al.   Journal of Parkinsons Disease

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease

(2019) Alan Whone et al.   BRAIN

Trial of magnetic resonance–guided putaminal gene therapy for advanced Parkinson's disease

(2019) John D. Heiss et al.   MOVEMENT DISORDERS

A Novel Small Molecule Supports the Survival of Cultured Dopamine Neurons and May Restore the Dopaminergic Innervation of the Brain in the MPTP Mouse Model of Parkinson’s Disease

(2019) Oleg V. Ardashov et al.   ACS Chemical Neuroscience

Non-motor features of Parkinson disease

(2017) Anthony H.V. Schapira et al.   NATURE REVIEWS NEUROSCIENCE

Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?

(2017) Raymond T. Bartus et al.   NEUROBIOLOGY OF DISEASE

Dicer and microRNAs protect adult dopamine neurons

(2017) Piotr Chmielarz et al.   Cell Death & Disease

A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat

(2017) Yulia A. Sidorova   Frontiers in Pharmacology

Zebrafish GDNF and its co-receptor GFRα1 activate the human RET receptor and promote the survival of dopaminergic neurons in vitro

(2017) Tuulia Saarenpää et al.   PLoS One

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease

(2016) Pia Runeberg-Roos et al.   NEUROBIOLOGY OF DISEASE

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

(2015) C. Warren Olanow et al.   ANNALS OF NEUROLOGY

GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease

(2015) Edgar R. Kramer et al.   FEBS LETTERS

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Identification of a Vav2-dependent mechanism for GDNF/Ret control of mesolimbic DAT trafficking

(2015) Shuyong Zhu et al.   NATURE NEUROSCIENCE

GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function

(2015) Anmol Kumar et al.   PLoS Genetics

Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models

(2011) Andrii Domanskyi et al.   FASEB JOURNAL

Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges

(2010) Jacob Eriksen et al.   JOURNAL OF NEUROCHEMISTRY

Medium-throughput computer aided micro-island method to assay embryonic dopaminergic neuron cultures in vitro

(2010) A. Planken et al.   JOURNAL OF NEUROSCIENCE METHODS

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Persephin signaling through GFRα1: The potential for the treatment of Parkinson's disease

(2010) Yulia A. Sidorova et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Multiple Molecular Pathways Are Involved in the Neuroprotection of GDNF Against Proteasome Inhibitor Induced Dopamine Neuron Degeneration In Vivo

(2008) Yunlan Du et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Activation of the extracellular signal‐regulated kinases 1 and 2 by glial cell line‐derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease

(2008) Niklas Lindgren et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

(2008) William J Marks et al.   LANCET NEUROLOGY